Years 6-10 (2007-2012) Journal Articles

  1. Adomat HH, Bains OS, Lubieniecka JM, Gleave ME, Guns ES, Grigliatti TA, Reid RE, Riggs KW.Validation of a sequential extraction and liquid chromatography-tandem mass spectrometric method for determination of dihydrotestosterone, androstanediol and androstanediol-glucuronide in prostate tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 1;902:84-95. Epub 2012 Jul 1.
  2. Agalliu I, Kwon E, Zadory D, Thompson J, Stanford JL, Ostrander EA.  Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.  Clin Cancer Res 2007;13(3):839-43.
  3. Agalliu I, Weiss NS, Lin DW, Stanford JL. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: A population-based study in middle-aged men. Cancer Causes and Control 2007;18:931-937.
  4. Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, Stanford, JL.  Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.  Br J Cancer 2007;97:826-831. PMCID: PMC2360390
  5. Agalliu I, Suuriniemi M, Prokunina-Olsson L, Johanneson B, Collins F, Stanford JL, Ostrander EA. Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study.  The Prostate 2008;68:740-747. PMCID: PMC2765224
  6. Agalliu I, Salinas CA, Hansten P, Ostrander EA, Stanford JL. Statin use and prostate cancer risk: a population-based case-control study. Am J Epidemiol 2008;168:250-260. PMCID: PMC2585510
  7. Agalliu I, Kwon EM, Salinas CA, Ostrander EA, Stanford JL. Genetic variation in DNA repair genes and prostate cancer risk: Results from a population-based study. Cancer Causes Control. 2010;21: 289-300. PMCID: PMC2811225
  8. Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, Stanford JL, Ostrander EA, Chanock S, Wang M-H, Mittal RD, Isaacs WB, Platz EA, Hayes RB.  Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.  Clin Cancer Res 2011 Mar 1;17(5):1075-81. PMC3059497
  9. Amory J K, Bush M A, Zhi H, Caricofe R B, Matsumoto A M, Swerdloff R S, Wang C, Clark R V.  Oral testosterone with and without concomitant inhibition of 5alpha-reductase by dutasteride in hypogonadal men for 28 days.  J.Urol. 2011;185(2):626-632.
  10. Aslan JE, You H, Williamson DM, Endig J, Youker RT, Thomas L, Shu H, Du Y, Milewski RL, Brush MH, Possemato A, Sprott K, Fu H, Greis KD, Runckel DN, Vogel A, Thomas G. Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis. Mol Cell. 2009 May 14;34(4):497-509. PMCID: PMC2744858
  11. Attardi B J, Marck B T, Matsumoto A M, Koduri S, Hild S A.  Long-term effects of dimethandrolone 17beta-undecanoate and 11beta-methyl-19-nortestosterone 17beta-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats.  J.Androl. 2011;32(2):183-192.
  12. Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ,…Stanford JL, …(52 co-authors).  Analysis of Xq27-28 linkage in the International Consortium for Prostate Cancer Genetics (ICPCG) families.  BMC Med Genet 2012 Jun 19;13(1):46.
  13. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20;44(6):685-9.
  14. Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C, Rocchi P. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011 Oct 20;2:e221. doi: 10.1038/cddis.2011.104. PMC3219088
  15. Beltran H, Rickman D, Park K, Sboner A, MacDonald TY, Terry S, Tagawa ST, Dhir R, Nelson J, de la Taille A, Allory Y, Wang Y, Collins C, Gleave M, Gerstein MB, Perner S, Pienta K, Chinnaiyan A, Demichelis F, Nanus DM, Rubin MA: Molecular characterization of neuroendocrine prostate cancer and identification of new drug target.  2011 Cancer Discovery.1(6):487-95. PMCID: PMC3290518
  16. Bentov I, Narla G, Schayek H, Akita K, Plymate SR, LeRoith D, Friedman SL, Werner H. Insulin-like growth factor-I regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology. 2008 Apr;149(4):1890-7.
  17. Beroukhim R, True LD, Meyerson M, et. al. (58 co-authors) The landscape of somatic copy number alteration across human cancer types. Nature. 463(7283):899-905, 2010. PMCID: PMC2826709
  18. Berry DL, Halpenny B, Hong F, Wolpin S, Lober WB, Russell KJ, Ellis WJ, Govindarajulu U, Bosco J, Davison BJ, Bennett G, Terris MK, Barsevick A, Lin DW, Yang CC, Swanson G. The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: A multi-center randomized trial. Urol Oncol. 2011 Dec 7. [Epub ahead of print] PMCID: PMC3349002
  19. Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS.  The effects of aging on the molecular and cellular composition of the prostate microenvironment.  PLoS One 2010;5(9):e12501. PMCID: PMC2931699
  20. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella RL, Fridman R, Cher ML. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 170:2100-2111; 2007. PMC1899437.
  21. Brasky TM, Kristal AR, Navarro SL, Lampe JW, Peters U, Patterson RE, White E.  Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort.  Nutr.Cancer 2011;63(4):573-582. PMCID: PMC3100666
  22. Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, Thompson IM, King IB, Albanes D, Kristal AR.  Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.  Am.J.Epidemiol. 2011;173(12):1429-1439. PMCID: PMC3145396
  23. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E.  Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort.  Cancer Epidemiol.Biomarkers Prev. 2010;19(12):3185-3188. PMCID: PMC3005534
  24. Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC.  Osteoclast-derived matrix metalloproteinases-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.   Mol Cancer Res 2010 Apr;8(4):459-70. PMCID: PMC2946627
  25. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012 Feb 14;106(4):768-774. doi: 10.1038/bjc.2011.595. Epub 2012 Jan 12. PMCID: PMC3322952
  26. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon N, Wang H, Chen S, Balk SP. Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors. Cancer Res. 2011 Aug 25.
  27. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011 Oct 18;20(4):457-71. PMCID: PMC3225024
  28. Camp NJ, Cannon-Albright LA, Farnham JM, …Stanford JL, et al. (45 co-authors) Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Human Molecular Genetics 2007;16:1271-1278. PMCID: PMC2653215
  29. Catalona WJ, Bailey-Wilson JE, Camp NJ,…Stanford JL,… (19 co-authors).  National Cancer Institute Prostate Cancer Genetics Working Group Workshop: Meeting Report. Cancer Res 2011;71:3442-3446.
  30. Chang B-L, Spangler E, Gallagher S,…Stanford JL,… (32 co-authors). Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biom Prev 2011 Jan;20(1):23-32. PMCID: PMC3110616
  31. Cheever MA, Higano CS.  PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.  Clin.Cancer Res. 2011;17(11):3520-3526.
  32. Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF Jr, Vessella RL, Atfi A, Dong JT. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26:2386-2394; 2007.
  33. Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 18:237-47; 2009. PMCID: PMC2853938
  34. Chi KN, Zoubeidi A, Gleave ME, Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs 19:1955-62; 2008. PMID:19012510
  35. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl B, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase 2 study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration resistant prostate cancer. J Clin Oncol 28:4247-4254; 2010.
  36. Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M.  A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. Clin Cancer Res. 2012 Jun 15;18(12):3407-13. Epub 2012 May 2. IF: 7.742
  37. Chiu HH, Yong TM, Wang J, Wang Y, Vessella RL, Ueda T, Wang YZ, Sadar MD.  Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.  Cancer Letter. 2009 Jun 28; 292:176-185.
  38. Christensen GB, Baffoe-Bonnie AB, George A, …Stanford JL…(46 co-authors). Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. The Prostate 2010;70(7):735-44.
  39. Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng HW, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demicheli F, Beltran H, Hirst M, Marra M, Gleave M, Lubin M, Wang Y. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target. Mol Cancer Ther. 2012 Mar;11(3):775-83. Epub 2012 Jan 17.
  40. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008 Dec 2;6(12):2853-68. PMCID: PMC2592359
  41. Datta MW, True LD,  Nelson PS, Amin MB. The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol. 2007 Nov;14(6):408-18.
  42. Dattoli M, Wallner K, True L, Bostwick D, Cash J, Sorace R.  Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy.  J.Oncol. 2010;2010:471375. Epub 2010 Aug 18. PMCID: PMC2933915
  43. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel AR exon generates a constituitively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-5477; 2008. PMC2663383.
  44. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, True L, Rubin MA, Adam RM, Beroukhim R, Freeman MR. Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009 Jul 1;69(13):5601-9. PMCID: PMC2853876
  45. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li !, Vessella RL, Kibel AS, Stevens VI, Calle EE, and Dong JT.  SnoRNA U50 is a candidate tumor suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.  Hum Mol Genet. 2008 Apr 1; 17:1031-1042. PMCID: PMC2923223.
  46. Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents. Curr Opin Urol. 2012 May;22(3):190-6.
  47. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, et. al; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons’ Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009 Oct;41(10):1116-21. PMCID: PMC2846760
  48. Feng Z. Classification versus association models: should the same methods apply? Scandinavian Journal of Clinical and Laboratory Investigation, 2010 Jul;242:53-8. PMCID: PMC3140431.
  49. Fesinmeyer MD, Kwon EM, Ru R, Ostrander EA, Stanford JL. Variation in RNASEL and risk for prostate cancer in a population-based case-control study. The Prostate 2011 Feb 25. [Epub ahead of print]. PMCID: PMC3130811
  50. Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Vessella RL, Vicentini C, Bologna M.  Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.   Endocr Relat Cancer. 2007 Aug 7; 14:601-611.
  51. FitzGerald LM, Karlins E, Karyardi DM, Kwon EM, Stanford JL, Ostrander EA.  Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis. 2009;12(2):192-7. PMCID: PMC2790323
  52. FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, Feng A, Ostrander EA, Stanford JL.  Genome-wide association study identifies a genetic variant associated with risk for aggressive prostate cancer.  Cancer Epidemiol Biom Prev 2011 Jun;20(6):1196-203. PMCID: PMC3111761
  53. FitzGerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.  Clin Cancer Res. 2009 May 1;15(9):3231-7. PMCID: PMC2707085
  54. FitzGerald LM. Agalliu I. Johnson K. Miller MA. Kwon EM. Hurtado-Coll A. Fazli L. Rajput AB. Gleave ME. Cox ME. Ostrander EA. Stanford JL. Huntsman DG.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.  BMC Cancer. 2008 Aug 11;8:230. PMCID: PMC2519091
  55. FitzGerald LM, Thomson R, Polanowski A, Patterson B, McKay JD, Stankovich J, Dickinson JL. Sequence variants of α-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population. Prostate 68:1373-9; 2008. PMID:18537123.
  56. FitzGerald LM, Patterson B, Thomson R, Polanowski A, Quinn S, Brohede J, Thornton T, Challis D, Mackey DA, Dwyer T, Foote S, Hannan GN, Stankovich J, McKay JD, Dickinson JL. Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur J Hum Genet 17:368-77; 2009. PMCID: PMC2986161
  57. FitzGerald LM, McDonnell SK, Carlson EE, Langeberg WJ, McIntosh LM, Deutsch K, Ostrander EA, Schaid DJ, Stanford JL.  Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a prostate cancer susceptibility locus on 15q11-q14. Eur J Hum Genet 2010 Oct;18(10):1141-7. PMCID: PMC2921483
  58. FitzGerald LM, Zhang X, Kolb S, Kwon EM, Liew YC, Hurtado-Coll A, Knudsen BS, Ostrander EA, Stanford JL.  Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat 2012 Aug 7. doi: 10.1002/humu.22176. [Epub ahead of print]. NIHMSID: NIHMS402519
  59. Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res. 2010 Apr 15;70(8):3239-48. PMCID: PMC2999007
  60. Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh CC, Adisetiyo H, Roy-Burman P, Coleman I, Nelson PS, Vessella RL, Davis RJ, Plymate SR, Mercurio AM. VEGF/Neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-1R define a novel mechanism of aggressive prostate cancer. Cancer Discov. 2012 Jul 9. [Epub ahead of print]
  61. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.  Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.  Cancer Causes Control 2008;19:25-31.
  62. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.  Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.  Cancer 2007; 109(6):1192-202.
  63. Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer. 2009 Aug 15;115(16):3661-9. PMCID: PMC2739798
  64. Gore JL, Wright JL, Daratha KB, Roberts KP, Lin DW, Wessells H, Porter M. Hospital-level variation in the quality of urologic cancer surgery. Cancer. February 2012; 118(4): 987-96. PMCID: PMC3273633
  65. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P.  Prostate-specific antigen best practice statement: 2009 update. J Urol 2009;182:2232-2241.
  66. Gulati R, Mariotto A, Chen S, Gore J, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. Journal of Clinical Epidemiology. December 2011; 64(12): 1412-7.
  67. Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, Greasley S, Nagata A, Burke BJ, Edwards M, Hosea N, Kang P, Hu W, Engebretsen J, Briere D, Shi M, Gukasyan H, Richardson P, Dack K, Underwood T, Johnson P, Morell A, Felstead R, Kuruma H, Matsimoto H, Zoubeidi A, Gleave M, Los G, Fanjul AN. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem. 2011 Nov 10;54(21):7693-704. Epub 2011 Oct 7. J Med Chem. 2011 Nov 10;54(21):7693-704. Epub 2011 Oct 7.
  68. Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME, Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. Int J Cancer 122:2368-76; 2008.
  69. Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med. 2012 Aug;4(8):743-760.
  70. Haiman CA, Chen GK, Blot WJ, Strom SS, Bernt S, Kittles RA, Rybicki BA, Isaacs W, Ingles SA, Stanford JL, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011 May;7(5):e1001387. Epub 2011 May 26. PMCID: PMC3102736
  71. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs W, Ingles SA, Stanford JL, et al. Genome-wide association study of prostate cancer in men of African descent reveals a novel susceptibility locus at 17q12. Nat Genet 2011 Jun;43(6):570-3. PMCID: PMC3102788
  72. Harris JN, Bowen DJ, Kuniyuki A, McIntosh L, FitzGerald LM, Ostrander EA, Stanford JL. Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genet Med. 2009 May;11(5):344-55. PMCID: PMC2683189
  73. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009 Feb;6(2):76-85. PMCID: PMC2981403
  74. Hawkins V, Chubak J, Sorensen B, Ulrich CM, Stancyzk FZ, Plymate S, Stanford JL, et al. Effect of exercise on serum sex hormones in men: a 12-month randomized controlled clinical trial. Medicine and Science in Sports and Exercise 2008;40:223-233. PMCID: PMC3040039.
  75. Hayashi N, Koller E, Fazli L, Gleave ME. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate 2008 Sep 1;68(12):1283-95.
  76. Hayashi N, Peacock JW, Beraldi E, Zoubeidi A, Gleave ME, Ong CJ. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ. 2012 Jun;19(6):990-1002. doi: 10.1038/cdd.2011.184. PMCID: PMC3354053
  77. Higano C S, Small E J, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff P W.  Sipuleucel-T.  Nat.Rev.Drug Discov. 2010;9(7):513-514.
  78. Holcomb IN, Grove DI, Kinnunen M, Friedman C, Gallaher I, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res. 2008 Jul 15;68(14):5599-608. PMCID: PMC2613025
  79. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MR, Morrissey CM, Higano CS, Nelson PS, Vessella RL and Trask BJ.  Comparative analyses of chromosomal alterations in soft-tissue metastases within and across patients with castration resistant prostate cancer.  Cancer Res 2009 69:7793-7802.  PMCID: PMC2771763.
  80. Holick CN, Stanford JL, Kwon E, Ostrander EA, Nejentsev S, Peters U.  Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16 (10):1990-99.
  81. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA.  Association of megalin genetic polymorphisms with prostate cancer risk and prognosis.  Clin Cancer Res 2008 Jun 15;14(12):3823-31. PMCID: PMC2675883
  82. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, Peters U, Stanford JL. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010 Sep 15;70(13):1448-60. PMCID: PMC2927712
  83. Holt SK, Kwon EM, Lin DW, Koopmeiners JS, Ostrander EA, Feng Z, Stanford JL. Association of Hepsin Gene Variants with Prostate Cancer Risk and Prognosis. Prostate. 2010 Jun 15;70(9):1012-9. PMCID: PMC2875316
  84. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biom Prev 2009 Jun;18(6):1929-33. PMCID: PMC2743676
  85. Holt SK, Salinas CA, Stanford JL.Vasectomy and the risk of prostate cancer. J Urol. 2008 Dec;180(6):2565-7. Epub 2008 Oct 19. PMCID: PMC2582972
  86. Holt SK, Kwon EM, Fu R, Feng Z, Ostrander EA, Stanford JL.  Association of variants in estrogen-related pathway genes with prostate cancer risk.  The Prostate 2012 May 1. doi: 10.1002/pros.22534. [Epub ahead of print] NIHMSID: NIHMS385496
  87. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS and Luo J.  Ligand-independent androgen receptor variants derived from splicing of   cryptic-exons signify hormone refractory prostate cancer. Cancer Res. 2009 Jan 1; 69:16-22. PMCID: PMC2614301.
  88. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012 Jul 15;72(14):3457-62. Epub 2012 Jun 18. PMC3415705
  89. Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M and Nelson PS.  Molecular alterations in prostate carcinoma that associate with in vivo exposure to chemotherapy:  identification of a cytoprotective mechanism involving growth differentiation factor 15.  Clin Cancer Res 2007 Oct 1;13(19):5825-33.
  90. Huang Y, Pepe M, Feng Z. Evaluating the predictiveness of a continuous marker. Biometrics 2007;63:1181-1188. PMID: 17489968. PMCID: PMC3059154.
  91. Huang Y, Isharwal S, Haese A, Chun F, Makarov D, Feng Z, Han M, Humphreys E, Epstein J, Partin A, Veltri R. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous PSA measurement, clinical stage and biopsy Gleason score. BJU International, 2011 May;107(10):1562-9. PMCID: PMC3082635.
  92. Hubbard RA, Inoue LY, Fann JR. Modeling nonhomogeneous Markov processes via time transformation. Biometrics. 2008 Sep;64(3):843-50. Epub 2007 Nov 19.
  93. Inoue LY, Neira M, Nelson C, Gleave M, Etzioni R. Cluster-based network model for time-course gene expression data. Biostatistics. 2007 Jul;8(3):507-25.
  94. Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells. PLoS One. 2012;7(8):e42564. Epub 2012 Aug 3. PMCID: PMC3411798
  95. Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright, Camp NJ, Terrlink CC, FitzGerald LM, Stanford JL, et al. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: Evidence from the International Consortium for Prostate Cancer Genetics (ICPCG).  Human Genet 2012;131:1095-103. NIHMS403275
  96. Johanneson B, Deutsch K, McIntosh L. Friedrichsen DM, Janer M, Kwon EM, Iwasaki L, Hood L, Ostrander EA, Stanford JL.  Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer. The Prostate 2007;67:732-42.
  97. Johanneson B, McDonnell SK, Karyadi DM, Hebbring SJ, Wang L, Deutsch K, McIntosh L, Kwon EM, Suuriniemi M, Stanford JL, Schaid DJ, Ostrander EA, Thibodeau SN. Fine-mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. Hum Genet 2008;123:65-75.
  98. Johanneson B, McDonnell SK, Karyadi DM, Quignon P, McIntosh L, Riska SM, FitzGerald LM, Johnson G, Deutsch K, Williams G, Tillmans LS, Stanford JL, Schaid DJ, Thibodeau SN, Ostrander EA. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum Mol Genet. 2010 Oct 1;19(19):3852-62. PMC2935853
  99. Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M, Groskopf J, Rittenhouse HG, Vessella RL, Reynolds MA. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer. 2010 Jul 2; 9:174. PMCID: PMC2903503.
  100. Kalhorn TF, Page ST, Howald WN, Mostaghel EA, Nelson PS. Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007 21(19):3200-3206.
  101. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.  N.Engl.J.Med. 2010;363(5):411-422.
  102. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10. PMCID:PMC2538886
  103. Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M, Miller AD. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol. 2009 Jul;83(14):7353-6. Epub 2009 Apr 29. PMCID: PMC2704771
  104. Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, Davies JE, Maqsodi B, McMaster GK Kristal AR.   Evaluation of the branched chain DNA assay for measurement of RNA in formalin-fixed tissues.   Mol. Diagn 2008 Mar;10(2):169-76. PMCID: PMC2259472
  105. Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Woude GV, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):57-67. PMCID: PMC2952101
  106. Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, Zhau HE, Chung LW, Vessella RL. Serum prosaposin levels are increased in patients with advanced prostate cancer. Prostate. 2012 Feb;72(3):253-269. doi: 10.1002/pros.21427. Epub 2011 May 31. PMCID: PMC3406735
  107. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, and Corey E.  Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.  Br J Cancer. 2009 Jul 21; 101:263-268. PMCID: PMC2720213.
  108. Koreckij TD, Trauger RJ, Montgomery RB, Pitts TE, Coleman I, Nguyen H, Reading CL, Nelson PS, Vessella RL, Corey E. HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia. 2009 Nov;11:1216-1225. PMCID: PMC2767223.
  109. Koreckij TD, Hill C, Azure L, Nguyen HM, Kunz LL, Azure A, Corey E, Lange PH and Vessella RL.  Low dose alternating electric current inhibits growth of prostate cancer.  Prostate. 2010 Apr 1; 70:529-539.
  110. Kote-Jarai Z, Easton D, Stanford JL, Ostrander EA, Schleutker J, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.  Cancer Epidemiol Biom Prev 2008;17:2052-2061. PMCID: PMC2776652
  111. Kote-Jarai Z, Al Olama AA, Giles GG,…Stanford JL,… (127 co-authors). Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.  Nat Genet 2011;43 (8):785-791.
  112. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010 Apr;50(4):298-301. Erratum in: Methods. 2010 Nov;52(3):268.
  113. Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME: Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer. Mol Cancer Ther. 2012 Aug; 11(8): 1661-71
  114. Kumar A, Shendure J, Nelson PS. Genome interrupted: sequencing of prostate cancer reveals the importance of chromosomal rearrangements. Genome Med. 2011 Apr 19;3(4):23. PMCID: PMC3129639.
  115. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17087-92. Epub 2011 Sep 26. PMCID: PMC3193229
  116. Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, Ostrander EA. Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention. 2011 May;20(5):923-33. Epub 2011 Mar 23. PMCID: PMC3140053.
  117. Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, Ostrander EA.  Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.  Cancer Epidemiol 2012 Apr 26. [Epub ahead of print] PMCID: PMC3392409
  118. Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochem Biophys Acta 1805:17-24; 2010.
  119. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A: A novel HSP90 inhibitor delays castrate resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res. 2011 Apr 15;17(8):2301-13.
  120. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME. Clusterin Inhibition using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate Resistant Prostate Cancer. Cancer Res. 2011 Sep 1;71(17):5838-49.
  121. Lange P H.  Words of wisdom. Re: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Morris MJ, Huang D, Kelly WK, et al. Eur Urol 2009;56:237-44.  Eur.Urol. 2010;58(2):311-312.
  122. Lange T, Ullrich S, Müller I, Nentwich MF, Stübke K, Feldhaus S, Knies C, Hellwinkel OJ, Vessella RL, Abramjuk C, Anders M, Schröder-Schwarz J, Schlomm T, Huland H, Sauter G, Schumacher U. Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1,6)-branched oligosaccharides as a marker of tumor progression. Clin Cancer Res. 2012 Mar 1;18(5):1364-1373. Epub 2012 Jan 18. PMID: 22261809
  123. Langeberg WJ, Isaacs WB, Stanford JL.  Genetic etiology of hereditary prostate cancer.  Frontiers in Bioscience 2007;12:4101-10.
  124. Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA, Stanford JL. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biom Prev 2010;19:258-64. PMCID: PMC2825566
  125. Langeberg WJ, Tahir SA, Kwon EM, Feng Z, Ostrander EA, Thompson TC, Stanford JL. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 2010 Jun 15;70(9):1020-35. PMCID: PMC2875326
  126. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC: From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012 Jul;227(3):286-97. doi: 10.1002/path.4047. PMID: 22553170  IF: 6.318
  127. Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D. Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. J Thorac Oncol. 2012 Mar;7(3):579-586
  128. Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, Dhillon J, Jones SJ, Gleave ME, Eaves CJ, Dunn SE. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One. 2010 Sep 10;5(9).
  129. Lewinshtein D J, Porter C R, Nelson P S.  Genomic predictors of prostate cancer therapy outcomes.  Expert Rev.Mol.Diagn. 2010;10(5):619-636.
  130. Lewinshtein D, Gulati R, Nelson PS, Porter CR. Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. British Journal of Urology International. 2012 Mar;109(5):706-12. PMCID: PMC21883828
  131. Li N, Zoubeidi A, Beraldi E, Gleave ME: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene. 2012 Jun 11. doi: 10.1038/onc.2012.212. [Epub ahead of print]
  132. Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res. 2012 Apr;10(4):494-503. Epub 2012 Jan 30. PMID: 22290877
  133. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012 Jan 23. doi: 10.1038/onc.2011.637. [Epub ahead of print] PMCID: PMC3337879
  134. Liang Y, Ankerst DP, Feng Z, Fu R, Stanford JL, Thompson IM.  The risk of biopsy-detectable prostate cancer using the Prostate Cancer Prevention Trial risk calculator in a community setting. Urol Oncol 2012 May 1. [Epub ahead of print]. PMCID: PMC3426631
  135. Lin B, Utleg AG, Graydal K, White JT, Lalvorsen OJ, Lu W, True LD, Vessella RL, Lange PH, Nelson PS, Hood L, Kalland KH and Aksien LA.  WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res. 2008 Mar 1;14:1397-1406.
  136. Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave ME, Squire JA, Wang YZ. ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Research 68:4352-9; 2008.
  137. Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, GrÖnberg H, Stanford JL. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biom Prev 20:1928-36; 2011. PMCID: PMC3169727
  138. Lin DW, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, Kristal AR. Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues. Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2150-4.
  139. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009 Jul 1;115(13):2863-71. PMC2948666
  140. Linsen SE, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, Wyman SK, de Bruijn E, Voest EE, Kuersten S, Tewari M, Cuppen E. Limitations and possibilities of small RNA digital gene expression profiling. Nat Methods 6:474-6; 2009.
  141. Liu G, Atteridge CL, Lundgren AD, Wang X, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates shedding of MICA independent of ADAMs. J Immunol 184:3346-50; 2010.
  142. Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST, Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Grönberg H, Isaacs WB, Xu J. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene. 2011 Dec 5. doi: 10.1038/onc.2011.554. [Epub ahead of print]
  143. Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 70:239-51, 2010.
  144. Lu L, Giles GG, Severi G, Hopper JL, English DR, Foulkes WD,…Stanford JL,…(48 co-authors).  Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. The Prostate 2012;72:410-426.
  145. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ.  Screening, treatment and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med 2008;23(11):1809-14. PMCID: PMC2585661
  146. Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R, and Nelson PS. The Androgen-Regulated Type II Serine Protease TMPRSS2 is Differentially Expressed and Mislocalized in Prostate Adenocarcinoma. J Pathol. 2008 Jun;215(2):118-25.
  147. Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One. 2011;6(11):e27720. Epub 2011 Nov 16. PMC3218022
  148. Lutz BR, Dentinger CE, Nguyen LN, Sun L, Zhang J, Allen AN, Chan S, Knudsen BS. Spectral analysis of multiplex Raman probe signatures. ACS Nano. 2008 Nov 25;2(11):2306-14. PMCID: PMC2662378
  149. Maki H, Saramaki O, Martikainen P, Tammela T, van Weerden W, Vessella R, Cato A and Visakorpi T.  Overexpression and gene amplification of BAG-1L in hormone refractory prostate cancer.  J Pathol. 2007 Aug;212(4):395-401.
  150. Maresh E L, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind E S, Knutzen L A, Zhou Y, Chia D, Liu A Y, Goodglick L.  Differential expression of anterior gradient gene AGR2 in prostate cancer.  BMC Cancer 2010;10:680. PMCID: PMC3009682
  151. Marks LS, Mostaghel EA, Nelson PS. Prostate Tissue Androgens: History and Current Clinical Relevance. Urology. 2008 Aug;72(2):247-54.
  152. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG.The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011 May 20;30(13):2719-33.
  153. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, Rostomily R, Born D, Horwitz M, Ware C, Blau CA, Cleary MA, Rich JN, Ruohola-Baker H. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71:4640-52; 2011. PMCID: PMC3129496.
  154. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Wright GL, Yasui Y, Zhang Z, Zhu L, Semmes J.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clinical Chemistry. 2008;54:44-52.
  155. Mecham B, Nelson PS, Storey JD. Supervised normalization of microarrays. Bioinformatics. 2010 May 15;26(10):1308-15. PMCID: PMC2865860
  156. Mendiratta P, Mostaghel EA, Guinney J, Tewari AK, Porrello A, Barry W, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 27:2022-2029, 2009.
  157. Meng J, Mostaghel E, Vakar-Lopez F, Montgomery B, True L, Nelson P. Testosterone Regulates Tight Junction Proteins and Influences Prostatic Autoimmune Responses. Hormones and Cancer. 2011 Jun;2(3):145-56.
  158. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, and Rubin MA. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia. 2007 Mar;9(3):200-6. PMCID: PMC1838578
  159. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M.  Circulating microRNAs as stable blood-based markers for cancer detection.  Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. PMCID: PMC2492472
  160. Mo F, Wyatt AW, Wu C, Lapuk AV, Marra MA, Gleave ME, Volik SV, Collins CC: Next generation sequencing of prostate tumours suggests XMRV contamination not infection. 2012 J Clin Microbiol. Feb;50(2):536-7 Epub 2011 Dec 7. PMCID: PMC3264157
  161. Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer. 2010 May 28;10:244. PMCID: PMC2889894
  162. Montgomery RB, Mostaghel EA, Vessella RL, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.  Maintenance of intratumoral androgens in metastatic prostate cancer: A  mechanism for castration-resistant tumor growth.  Can Res 2008 Jun 1;68(11):4447-54. PMCID: PMC2536685
  163. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: a phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer. 2007 Sep 1;110(5):996-1002.
  164. Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 2009 Mar;9(2):237-49. Review. PMC2921605
  165. Morgan T, Lange PH and Vessella RL.   Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci, 2007 May 1;12:3000-9.
  166. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS and Vessella RL.  Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.  Clin Cancer Res. 2009 Jan 15;15(2):677-83. PMCID: PMC3162324
  167. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL and Corey E.  RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and Zoledronic acid.   Prostate, 2008 Jun 1;68(8):861-71.
  168. Morgan T M, Welty C J, Vakar-Lopez F, Lin D W, Wright J L.  Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.  J.Urol. 2010;184(6):2303-2307. PMCID: PMC3111052
  169. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. Journal of Cellular Biochemistry. J Cell Biochem 101:873-86; 2007.
  170. Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer 7:148; 2007. PMCID: PMC2034387
  171. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E.  Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.  Neoplasia 2010 12:192-205.  PMCID: PMC2814357.
  172. Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC, True LD, Corey E, Vessella RL. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 70(16):1799-808, 2010. PMCID: PMC3104406
  173. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T.  Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 2010 21:423-432. PMCID: PMC2953769
  174. Morrissey C, Lai JS, Brown LG, Wang Y, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS and Vessella RL.  The expression of osteoclastogenesis-associated factors and osteoblastic response to osteolytic prostate cancer cells.  2010 Prostate 70:412-424. PMC2929015
  175. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang Y, Corey E, Lange PH, Higano CS and Vessella RL.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.  Clin Exp Metastases 2008;25(4):377-88. Epub 2007 Oct 31.
  176. Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate cancer: results from the University of Washington rapid autopsy series. J Bone Miner Res. 2012 Aug 30. doi: 10.1002/jbmr.1749. [Epub ahead of print]
  177. Mostaghel EA, Montgomery RB, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic PCa: A mechanism for castration-resistant tumor growth. Cancer Research 68:4447-4454, 2008. PMCID: PMC2536685
  178. Mostaghel EA, Marck B, Plymate S, Vessella RL, Balk SP, Matsumoto AM, Nelson PS, Montgomery B. Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011 Sep 15;17(18):5913-25. PMC3184252.
  179. Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, Nelson PS. Variability in the androgen response of prostate epithelium to 5-alpha reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res. 2010 Feb 15;70(4):1286-95. PMCID: PMC2822890
  180. Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol. 2009 May-Jun;27(3):251-7. Review. PMC2705999
  181. Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):243-58. PMCID: PMC2474812
  182. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremmer WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist following testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research 2007; 67(10): 5033-41.
  183. Mostaghel EA, Wright JL, Montgomery B, Stanford JL. SLCO Transport Genes in Prostate Cancer – Response to Letter to the Editor. Cancer Epidemiol Biomarkers Prev. 2011 Aug 9. [Epub ahead of print].
  184. Mostaghel EA, Plymate S. New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am. 2011 Sep;40(3):625-42. PMCID: PMC3167094.
  185. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. PLOS One. 2012;7(1):e30062. PMCID: PMC3261168
  186. Mostaghel EA, Lin DW, Amory JK, Wright JL, Marck BT, Nelson PS, Matsumoto AM, Bremner WT and Page ST (2012) Impact of Male Hormonal Contraception on Prostate Androgens and Androgen Action in Healthy Men: A Randomized Controlled Trial. (2012) Clin Endocrinol Metab. 2012 Aug;97(8):2809-17. PMCID: PMC3410271
  187. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M, Wu H: Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012 Apr 1;72(7):1878-89. Epub 2012 Feb 20. PMCID: PMC3319847
  188. N’Diaye A, Chen GK, Palmer CD,…Stanford JL,…(78 co-authors). Identification, replication, and fine-mapping of loci associated with adult height in individuals of African ancestry. PLoS Genet 2011;Oct; 7(10):e1002298. PMCID: PMC3188544
  189. Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res. 2008 Sept 15; 14(18):5769-77.
  190. Newcomb L, Brooks J, Carroll P, Feng Z, Gleave M, Nelson P, Thompson I, Lin DW. Canary prostate active surveillance study (PASS); design of a multi-institutional active surveillance cohort and biorepository. Journal of Urology, 2010 Feb;75(2):407-13.
  191. O’Brien CA, True LD, Higano CS, Rademacher BS, Garzotto M, Beer TM. Histological changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in high-risk prostate cancer patients. Am J Clinical Pathology 133(4):654-61, 2010. PMCID: PMC3047497
  192. O’Malley KJ, Langmann G, Ai J, Ramos-Garcia R, Vessella RL, Wang Z. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate. 2012 Jul 1;72(10):1117-1123. doi: 10.1002/pros.22458. Epub 2011 Dec 7. PMCID: PMC3319476
  193. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab. 2011 Feb;96(2):430-7. PMCID: PMC3048323
  194. Page ST.  Physiologic role and regulation of intratesticular sex steroids.  Curr.Opin.Endocrinol.Diabetes Obes. 2011;18(3):217-223.
  195. Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, Samathanam CA, Mitchell R, De Marzo AM. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate. 2009 Apr 1;69(5):559-69. PMCID: PMC2875878
  196. Pascal L E, Ai J, Vencio R Z, Vencio E F, Zhou Y, Page L S, True L D, Wang Z, Liu A Y.  Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells.  Cancer.Microenviron 2011;4(1):51-59. PMCID: PMC3047627
  197. Pascal L E, Vencio R Z, Vessella R L, Ware C B, Vencio E F, Denyer G, Liu A Y.  Lineage relationship of prostate cancer cell types based on gene expression.  BMC Med.Genomics 2011;4:46. PMC3113924
  198. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 1;15(9):3223-30. PMCID: PMC2878092
  199. Pepe MS, Feng Z, Gu JW.  Invited commentary on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond.’ Statistics in Medicine. 2008;27:173–181, 2008.
  200. Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y. Integrating the predictiveness of a marker with its performance as a classifier. American Journal of Epidemiology 2008;167(3):362-368. PMCID: PMC2939738
  201. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classficiation or prediction: standards for study design. Journal of the National Cancer Institute. 2008, 100, 1432-1438. PMCID: PMC2567415.
  202. Pepe MS, Feng Z, Longton G, Koopmeiners J. Conditional Estimation of Sensitivity and Specificity from a Phase 2 Biomarker Study Allowing Early Termination for Futility. Statistics in Medicine. 2009: 28:762-779. PMCID: PMC2745932.
  203. Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, Klein JR, Lange PH, and Vessella RL. The detection and isolation of viable PSA positive epithelial cells by enrichment:  a comparison to standard PSA RT-PCR and its clinical relevance in prostate cancer.  Urol Oncol, 2007 May-Jun;25(3):214-20.
  204. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, soule HR, Bandyke TA, Weber MJ, Wu L and Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 1;68:629-639.
  205. Pierce BL, Friedrichsen-Karyadi DM, McIntosh L, Deutsch K, Hood L, Ostrander EA, Austin MA, Stanford JL. Genomic scan of 12 hereditary prostate cancer families having an occurrence of pancreas cancer. The Prostate 2007;67:410-15.
  206. Pierce BL, Kwon EM, Plymate S, Ostrander EA, Stanford JL.  Diabetes mellitus and prostate cancer risk. The Prostate 2008;68:1126-1132.
  207. Pierce BL, Biggs ML, DeCambre M, Reiner AP, Li C, Fitzpatrick A, Carlson CS, Stanford JL, Austin MA.  C-reactive protein, interleukin-6 and prostate cancer risk in men aged 65 years and older. Cancer Causes and Control 2009;20:1193-203. PMCID: PMC2846958
  208. Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res. 2011 Aug 1;71(15):5090-100.  PMC3148311.
  209. Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Wu JD. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res. 2007 Nov 1;13(21):6429-39.
  210. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 1;69(13):5568-74. Epub 2009 Jun 23. PMCID: PMC2884104
  211. Porkka KP, Pfeiffer M, Waltering KK, Vessella RL, Tammela TLJ and Visakorpi T.  MicroRNA expression profiling in prostate cancer.  Cancer Res. 2007 Jul 1;67(13):6130-5.
  212. Pritchard CC, Nelson PS.Gene expression profiling in the developing prostate. Differentiation. 2008 Jul;76(6):624-40. Epub 2008 May 7. Review.
  213. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 179:400-10; 2011. PMCID: PMC3123858.
  214. Qian DZ, Huang CY, O’Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM. Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res. 2009 May 1;15(9):3135-42. PMCID: PMC2929837
  215. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate. 2010 Mar 1;70(4):433-42. PMCID: PMC2931415
  216. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60:1238-43. PMCID: PMC2095486.
  217. Risk MC, Knudsen BS, Coleman I, Dumpit R, Kristal AR, Le Meur N, Gentleman R, True LD, Nelson PS, Lin DW. Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect. Clin Cancer Res. 2010 Nov 15;16(22):5414-23. PMCID: PMC2992073
  218. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, Fisher PB, Plymate SR, Wu JD. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR.Oncogene. 2011 May 19;30(20):2345-55. PMCID: PMC3112005
  219. Romanuik TL, Ueda T, Le N, Hailes S, Yong TM, Thomson T, Vessella RL, Sadar MD.  Novel biomarkers for prostate cancer including noncoding transcripts.  Am J Pathol. 2009 Dec; 175:2264-2276. PMC2789638.
  220. Roth MY, Page ST. A role for dihydrotestosterone treatment in older men? Asian J Androl 13:199-200; 2011.
  221. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL and Ott SM.  Histopathologic assessment of prostate cancer bone “osteoblastic” metastases.   J Urol 2008 Sep;180(3):1154-60. PMC2992811
  222. Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. Epub 2011 Jul 25.
  223. Salinas CA, Koopmeiners JS, Kwon E, Fitzgerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009 Mar 1;69(4):363-72. PMCID: PMC2788301
  224. Salinas CA, Kwon E, Carlson CS, Koopmeiners JS, Feng Z, Karyadi DM, Ostrander EA, Stanford JL.  Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk.  Cancer Epidemiol Biomarkers Prev 2008; 17(5):1203–13.
  225. Salinas CA, Kwon EM, Fitzgerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U, Stanford JL. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. American Journal of Epidemiology. 2010 Sep 1;172(5):578-90. Epub 2010 Aug 5. PMCID: PMC2950822.
  226. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L, ISUP Prostate Cancer Group.  International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling.  Mod.Pathol. 2011;24(1):6-15.
  227. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL and Visakorpi T. TMPRSS2:ERG fusion identifies a subpopulation of prostate cancers with a favorable prognosis. Clin Cancer Res 2008 Jun 1;14(11):3395-400.
  228. Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, Jarvi KA, Diamandis EP. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castrate-resistant prostate cancer. J Biol Chem. 2012 Aug 20. [Epub ahead of print]
  229. Schaid DJ, McDonnell SK, Carlson EE, Thibodeau SN, Ostrander EA, Stanford JL. Affected relative pairs and simultaneous search for two-locus linkage in the presence of epistasis. Genet Epidemiol 2007;31:431-449.
  230. Schaid DJ, Stanford JL, McDonnell SK, Suuriniemi M, McIntosh L, et al.  Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q.  Human Genet 2007;121:729-735.
  231. Schayek H, Bentov I, Sun S, Plymate SR, Werner H. Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res. 2010 May 15;316(9):1479-88. PMCID: PMC2873092
  232. Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 2009 15:1558-1565. PMCID: PMC2935172
  233. Schayek H, Seti H, Greenberg NM, Sun S, Werner H, Plymate SR. Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol. 2010 Jul 29;323(2):239-45. PMCID: PMC2896981
  234. Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, Ginsberg D, Plymate SR, Werner H.  Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Growth Horm IGF Res. 2010 Feb;20(1):68-72.
  235. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437-46; 2010. PMCID: PMC2948179.
  236. Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng LC, Lorentzen TD, Krasnoselsky AL, Wang P, Liu Y, Gurley KE, Amon LM, Schepmoes AA, Moore RJ, Camp DG 2nd, Chodosh LA, Smith RD, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG. Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics Clin Appl. 2011 Apr;5(3-4):179-88. PMCID: PMC3069718.
  237. Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J, Zarour L, Higano C, True LD, Vessella RL, Wilmot B, Bottomly D, McWeeney SK, Bova GS, Partin AW, Mori M, Alumkal J. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics. 2011 Oct 1;6(10):1248-56. Epub 2011 Oct 1. PMCID: PMC3225842
  238. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 2010 Dec 1;120(12):4478-92. PMCID: PMC2993601
  239. Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, Zoubeidi A, Gleave ME. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res. 2012 Aug 15. [Epub ahead of print] PMID: 22896337 IF: 7.856
  240. Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, Sorensen PH, Gleave ME. Clusterin Is a Critical Downstream Mediator of Stress-Induced YB-1 Transactivation in Prostate Cancer. Mol Cancer Res. 2011 Dec;9(12):1755-66. Epub 2011 Oct 10. PMID: 21987172 IF 4.373
  241. Siltanen S, Wahlfors T, Schindler M, Saramäki OR, Mpindi JP, Latonen L, Vessella RL, Tammela TL, Kallioniemi O, Visakorpi T, Schleutker J. Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells. PLoS One. 2011;6(10):e26595. Epub 2011 Oct 20. PMCID: PMC3197657
  242. Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Lin DW.  Tertiary Gleason Pattern 5 in Gleason 7 Prostate Cancer Predicts Pathological Stage and Biochemical Recurrence. J Urol. 2008 May;179(5):1775-9.
  243. Siva AC, Nelson LJ, Fleischer CL, Majlessi M, Becker MM, Vessella RL, Reynolds MA.  Molecular assays for the detection of microRNAs in prostate cancer.  Mol Cancer 2009 Mar 6;8:17. PMCID: PMC2656451
  244. Snyder C N, Clark R V, Caricofe R B, Bush M A, Roth M Y, Page S T, Bremner W J, Amory J K.  Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.  J.Androl. 2010;31(6):527-535. PMCID: PMC3047498
  245. So AI. HIFU ablation is not a proven standard treatment for localized prostate cancer. Can Urol Assoc J. 2011 Dec;5(6):424-6. doi: 10.5489/cuaj.11232.
  246. Sokoll LJ, Ellis W, Lange PH, Noteboom J,  Elliott DJ, Deras IL,  Blasé A, Koo S, Sarno M, Rittenhouse H,Groskopf J, and Vessella RL.  A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects,analytical performance, and diagnostic accuracy.  Clinica Chimica Acta. 2008 March 389:1-6.
  247. Sowery RD, Hadaschik BA, So A, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU 102:389-97; 2008.
  248. Sprenger CC, Haugk K, Sun S, Coleman I, Nelson PS, Vessella RL, Ludwig DL, Wu JD, Plymate SR. Transforming growth factor-{beta}-stimulated clone-22 is an androgen-regulated gene that enhances apoptosis in prostate cancer following insulin-like growth factor-I receptor inhibition. Clin Cancer Res. 2009 Dec 15;15(24):7634-7641. PMCID: PMC2795132
  249. Sprenger C C, Plymate S R, Reed M J.  Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.  Int.J.Cancer 2010;127(12):2739-2748.
  250. Stanford JL, FitzGerald LM, McDonnell SK, Carlson EE, McIntosh LM, Deutsch K, Hood L, Ostrander EA, Schaid DJ. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet. 2009 May 15;18(10):1839-48. Epub 2009 Feb 27. PMCID: PMC2671990
  251. Suikki HE, Kujala PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T. Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate 2010 Jun 1;70(8):889-98.
  252. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010 Aug 2;120(8):2715-30. PMC2912187
  253. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012 Aug 5. [Epub ahead of print] PMID: 22863786
  254. Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R,Singer FR, Hoon D. A multimarker circulating DNA assay for assessing prostate cancer patient’s blood. Clin Chem 55:559-567;2009. Epub 2009 Jan 8.
  255. Suuriniemi M, Agalliu I, Schaid DJ, Johanneson B, McDonnell SK, Iwasaki L, Stanford JL, Ostrander EA. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biom Prev 2007;16 (4):809-14.
  256. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Trans Med 3:85ra47; 2011.
  257. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate 70(16):1778-87, 2010.
  258. Taioli E, Flores-Obando RE, Agalliu I, Blanchet P, Bunker CH, Ferrell RE, …Stanford JL,…(24 co-authors). Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent.  Carcinogenesis 2011;32 (9):1361-65. PMCID: PMC3165127
  259. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010 Dec 16(12):1414-20. PMCID: PMC3088104.
  260. Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave ME, Snoek R, Rennie PS. TATA binding protein-associated factor 1 (TAF1) binds and differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin activating and conjugating domains. Mol Endocrinol 24:696-708; 2010.
  261. Telesca D, Inoue LYT, Neira M, Etzioni, R, Gleave M, Nelson, C. Differential Expression and Network Inferences through Functional Data Modeling Biometrics. 2009 Sep;65(3):793-804. PMC2956129
  262. Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther. 2011 Feb;10(2):347-59.
  263. Tischkowitz MD, Yilmaz A, Chen LQ, Karyadi DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA, Aloyz R, Nelson PS, Hood L, Narod SA, White KA, Ostrander EA, Isaacs WB, Offit K, Cooney KA, Stanford JL, Foulkes WD.  Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Letters 2008;270:173-180. PMCID: PMC2969172
  264. True LD, Jordan CD. The cancer nuclear microenvironment: Interface between light microscopic   cytology and molecular phenotype. J Cell Biochem. 2007 Aug15;104(6).
  265. True LD, Zhang H, Ye M, Huang C-Y, Nelson P, von Haller P, Tjoelker L, Kim J-S, Qian W, Smith R, Ellis W, Liu A. CD90/THY1 is over-expressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Modern Pathology. (10):1346-56, 2010. PMCID: PMC2948633
  266. True LD, Hawley S, Norwood TH, Braun KR, Evanko SP, Chan CK, LeBaron RC, Wight TN. The accumulation of versican in the nodules of benign prostatic hyperplasia. Prostate. 2009 Feb 1; 69:149-158.
  267. True LD. Quality control in molecular immunohistochemistry. Histochem Cell Biol. 2008 Sep;130:473-480. PMCID: PMC2522330.
  268. Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, Tammela TL, Vessella RL, Lähdesmäki H, Jänne OA, Visakorpi T. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene. 2012 Apr 26;31(17):2153-163.
  269. Vencio EF, Pascal LE, Page LS, Denyer G, Wang AJ, Ruohola-Baker H, Zhang S, Wang K, Galas DJ, Liu AY.  Embryonal carcinoma cell induction of miRNA and mRNA changes in co-cultured prostate stromal fibromuscular cells.  J.Cell.Physiol. 2011;226(6):1479-1488.
  270. Vermulst M, Bielas JH, Kujoth GC, Ladiges WC, Rabinovitch PS, Prolla TA, Loeb LA. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39:540-3; 2007.
  271. Vermulst M, Wanagat J, Kujoth GC, Bielas JH, Rabinovitch PS, Prolla TA, Loeb LA. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 40:392-4; 2008.
  272. Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, Rubin MA. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia. 9:200-206; 2007. PMCID: 1838578.
  273. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009 Jul 23;138:245-256. PMCID: PMC2726827.
  274. Wang G, Haile S, Comuzzi B, Tien AH, Wang J, Yong TM, Jelescu-Bodos AE, Blaszczyk N, Vessella RL, Masri BA and Sadar MD. Osteoblast-derived factors induce an expression signature that identifies      prostate cancer metastasis and hormonal progression. Cancer Res Cancer Res. 2009 Apr   15;69(8):3433-42.
  275. Wang D, Montgomery RB, Schmidt LJ, Mostaghel EA, Huang H, Nelson PS, Tindall DJ. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Research. 2009 Dec 15;69(24):9448-56. PMCID: PMC2795008
  276. Wang X, Lundgren AD, Singh P, Goodlett DR, Plymate SR, Wu JD. An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding. Biochem Biophys Res Commun. 2009 Sep 25;387(3):476-81. Epub 2009 Jul 16. PMCID: PMC2737406
  277. Watahiki A, Wang Y, Morris J, Dennis K, O’Dwyer HM, Gleave M, Gout PW, Wang Y. MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011;6(9):e24950. Epub 2011 Sep 30. PMC3184096
  278. White TA, Kwon EM, Fu R, Lucas F, Ostrander EA, Stanford JL, Nelson PS.  The monoamine oxidase A gene promoter repeat and prostate cancer risk. The Prostate 2012 Apr 2. doi: 10.1002/pros.22515. [Epub ahead of print]. NIHMSID: NIHMS360962
  279. Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG. A  targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat  Biotechnol. 2011 Jun 19;29(7):625-34.
  280. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thuroff JW, Vessella RL, Cher ML, Bonfil RD. C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia 10:993-1003; 2008. PMCID: PMC2517645
  281. Wikman H, Vessella RL, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS. 2008 Jul-Aug; 116(7-8):754-70.;jsessionid=479CC06F1C4F0F67A94BA29836D96DC6.d02t04
  282. Wright JL, DW Lin, Cowan JE, Carroll PR, Litwin MS and the CaPSURE Investigators. Quality of life in young men after radical prostatectomy. Prostate Cancer Prostatic Dis 11:67-73; 2008.
  283. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study.  Cancer Causes Control 2009;20:1617-22. PMCID: PMC2767519
  284. Wright JL, Lin DW. Prostate Cancer Risk Stratification by Genotype and PSA. Nat Rev Urol 6:641-2; 2009.
  285. Wright JL, Kwon E, Lin DW, Kolb S, Koopmeiners J, Feng Z, Ostrander EA, Stanford JL. CYP17 polymorphisms and prostate cancer outcomes. Prostate 2010 Jul 1;70(10):1094-101. PMC2878282
  286. Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA.  Expression of SLCO transport genes in castration resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.  Cancer Epidemiol Biom Prev 2011;20 (4):619-27. PMCID: PMC3073610
  287. Wright JL, Neuhouser ML, Lin DW, Kwon EM, Feng Z, Ostrander EA, Stanford JL.  AMACR polymorphisms, dietary intake and prostate cancer risk. The Prostate 2011 Apr;71(5):498-506. PMC3148811
  288. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009 Dec;182(6):2702-7. PMC2828768
  289. Wright JL, Page ST, Lin DW, Stanford JL.  Male pattern baldness and prostate cancer risk in a population-based case-control study.  Cancer Epidemiol 2010 Apr;34(2):131-5. PMCID: PMC2911123
  290. Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, Lin DW. Positive surgical margins at radical prostatectomy predict prostate cancer-specific mortality. J Urol 2010 Jun;183(6):2213-8. PMCID: PMC2903223
  291. Wright JL, Lin DW, Stanford JL. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate. 2011 Nov;71(15):1631-7. Epub 2011 Mar 22. PMC3409087
  292. Wright JL, Lin DW, Stanford JL. Circumcision and risk of prostate cancer.  Cancer 2012 Sep 15;118(18):4437-43. PMCID: PMC3376675
  293. Wright JL, Lin DW, Stanford JL. Reply to circumcision unlikely to be associated with prostate cancer risk. Cancer. 2012 Jun 28. [Epub ahead of print] PMID: 22744887
  294. Wright JL, Lin DW, Stanford JL.  The effect of demographic and clinical factors on the relationship between BMI and PSA levels. The Prostate 2011 Mar 22. [Epub ahead of print]
  295. Wu JD, Lin DW, Page ST, Lundgren AD, True LD, Plymate SR. Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol 2009 2:39-48. PMC2647701
  296. Wu, J.D., C.L. Atteridge, X. Wang, T. Seya, S. R. Plymate. Obstructing Shedding of the Immune Stimulatory MICB Prevents Tumor Formation – Implication for Targeted Cancer Therapy. Clin Cancer Res. 2009 Jan 15;15(2):632-40. PMCID: PMC2775521
  297. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmbhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Jones SJ, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Sahinalp SC, Gleave ME, Volik SV, Collins CC: Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol. 2012 May;227(1):53-61. doi: 10.1002/path.3987. Epub 2012 Mar 21.
  298. Wu C, Wyatt AW, McPherson A, Lin D, McConeghy BJ, Mo F, Shukin R, Lapuk AV, M Jones SJ, Zhao Y, Marra MA, Gleave ME, Volik SV, Wang Y, Sahinalp SC, Collins CC. Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer. 2012 Aug 25. doi: 10.1002/gcc.21999.
  299. Xie D, Gore C, Zhou J, Pong RC, Zhang H, Yu L, Vessella RL, Min W, Hsieh JT.  DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.  Proc Natl Acad Sci USA 2009 Nov 24; 106:19878-19883. PMCID: PMC2785260.
  300. Xia J, Trock B, Cooperberg M, Gulati R, Zeliadt S, Gore J, Lin D, Carroll P, Carter H, Etzioni R. Prostate Cancer Mortality Following Active Surveillance Versus Immediate Radical Prostatectomy. Clinical Cancer Research. 2012 (In press)
  301. Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS. Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression. Prostate. 2007 Nov 1;67(15):1621-9.
  302. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Feedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. SLCO2B1 and SLCO1B3 as pharmacogenomic determinants of resistance to androgen deprivation therapy in prostate cancer. J Clin Oncol 29:2565-73, 2011. PMCID: PMC3138634.
  303. You H, Thomas G. A homeostatic switch in PACS-2 links membrane traffic to TRAIL-induced apoptosis. Cell Cycle. 2009 Sep 1;8(17):2679-80.
  304. Youker RT, Shinde U, Day R, Thomas G. At the crossroads of homoeostasis and disease: roles of the PACS proteins in membrane traffic and apoptosis. Biochem J. 2009 Jun 12;421(1):1-15. Review.
  305. Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn 7:659-72; 2007.
  306. Yu EY, Wilding G, Posadas M, Gross M, Culine S, Massard C, Morris M, Hudes GR, Calabro F, Trudel GC, Sternberg CN. Phase 2 study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421-7428; 2009.
  307. Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Duration of first off treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol. 2010 Jun 1;28(16):2668-73. PMCID: PMC2881848
  308. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011 Mar 3;36(3):192-8. PMCID: PMC3129631
  309. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77:1166-1171; 2011.
  310. Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol. 2012 May 20;30(15):1864-70. Epub 2012 Apr 9. PMCID: PMC22493411
  311. Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW.  What happens after an elevated PSA test: the experience of 13,591 veterans.  J.Gen.Intern.Med. 2010;25(11):1205-1210. PMCID: PMC2947635
  312. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW.  Influence of publication of US and European prostate cancer screening trials on PSA testing practices.  J.Natl.Cancer Inst. 2011;103(6):520-523.
  313. Zhang X, Wang W, True LD, Vessella RL, Takayama TK.  Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastases.  Prostate 2009 May15;69(7):727-36. PMCID: PMC2720055
  314. Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, Müller S, Chen Z, Josson S, Coleman IM, Nelson PS, Wang YA, Wang R, Shin DM, Marshall FF, Kucuk O,  Chung LW, Zhau HE, Wu D. EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene. 2011 May 30. PMCID: PMC3165108.
  315. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011;6(11):e27970. Epub 2011 Nov 17. PMCID: PMC3219707
  316. Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol Cancer Ther. 2011 Dec;10(12):2309-2319. Epub 2011 Oct 25.
  317. Zhau HE, He H, Wang CY, Zayzafoon M, Morrissey C, Vessella RL, Marshall FF, Chung LW, Wang R. Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin Cancer Res 17(8):2159-69, 2011. PMCID: PMC3085118
  318. Zheng Y, Cai T, Stanford J, Feng Z. Semiparametric models of time-dependent predictive values of prognostic biomarkers. Biometrics. 2010 March; 66(1):50-60. PMCID: PMC2875380.
  319. Zhu Y, Stevens RG, Hoffman A, FitzGerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL. Testing the circadian gene hypothesis in prostate cancer: A population-based case-control study. Cancer Res 2009;69(24): 9315-22. PMCID: PMC2955869
  320. Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol Cancer Res 7:142-55; 2009.
  321. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res. 2010 Feb 15;16(4):1088-93. PMCID: PMC2822877
  322. Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LWJ, Nelson CC, Rennie PS, Gleave ME. Clusterin facilitates COMMD1 and I-κB degradation to enhance NF-κB activity in prostate cancer cells. Mol Cancer Res. 2010 Jan;8(1):119-30. PMCID: PMC2808437
  323. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007 Nov 1;67(21):10455-65.
  324. Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res. 2010 Mar 15;70(6):2307-17.
  325. Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol. 2012 Oct;44(10):1646-56. Epub 2012 May 6. PMID:22571949 IF: 4.634